A Phase II Study of Low dose ARA-C + Lenalidomide for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) without Deletion 5q in Patients Age 70 Years or Older Who Decline Remission Induction Chemotherapy

Trial Profile

A Phase II Study of Low dose ARA-C + Lenalidomide for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) without Deletion 5q in Patients Age 70 Years or Older Who Decline Remission Induction Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2015 Primary endpoint 'Complete clinical response rate' has been met as per the abstract presented at 20th Congress of the European Haematology Association.
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top